. 2018 Apr 19;78(7):781–785. doi: 10.1007/s40265-018-0907-5
© Springer Nature 2018, corrected publication May/2018
Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
Key milestones in the development of ibalizumab